Stock ALNFL NFL BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

NFL Biosciences Stock

Equities

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:04 2024-05-02 am EDT 		5-day change 1st Jan Change
1.84 EUR 0.00% Intraday chart for NFL Biosciences -15.21% +27.78%
Apr. 12 Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
Apr. 12 NFL Biosciences: successful capital increase CF

Financials

Sales 2023 200K 215K Sales 2024 * - Capitalization 14.92M 16M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 74.6 x
Net cash position 2023 * 2.3M 2.47M Net cash position 2024 * 200K 215K EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.13%
More Fundamentals * Assessed data

Chart NFL Biosciences

Dynamic Chart

Latest news about NFL Biosciences

Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
NFL Biosciences: successful capital increase CF
NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships MT
NFL Biosciences: success of smoking cessation study CF
NFL Biosciences Announces Patent Application Filed in the United States for Reducing Alcohol Consumption with NFL-301 & Preparation of a Pre-Ind Application Submission with the FDA CI
NFL Biosciences: GB Holding raises its stake CF
Global markets live: ABB, Bayer, UBS, Apple, Microsoft... Our Logo
NFL Biosciences SA Announces Management Changes CI
NFL BIOSCIENCES Announces Inclusion of the First Volunteer in the PRECESTO Study CI
Global markets live: Airbus, Walmart, Meta, Home Depot... Our Logo
NFL Biosciences SA announced that it has received €1.7 million in funding from Bpifrance Investissement SAS CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing... Our Logo
NFL Biosciences Raises EUR3 Million In Latest Funding Round MT
NFL Biosciences Kicks Off Nearly EUR3 Million Fundraising MT
NFL Biosciences On Track to Complete Trial on Smoking Cessation Treatment by Year-end MT
More news

Press releases NFL Biosciences

NFL Biosciences : further strengthens its operational team with the arrival of a Head of Development and Manufacturing PU
NFL Biosciences : renforce son équipe opérationnelle avec l’arrivée d’une Responsable du développement et de la fabrication PU
NFL Biosciences : Successful capital increase for NFL Biosciences with over €3 million raised PU
NFL Biosciences : launches a fundraising round for 3 million euros through a capital increase PU
NFL Biosciences : lance une levée de fonds d’environ 3 millions d’euros par voie d’augmentations de capital PU
More press releases

News in other languages on NFL Biosciences

NFL Biosciences : succès de l'augmentation de capital
Apple et le PPI sauvent l'Amérique
Hipay : Riber... les valeurs à suivre aujourd'hui à Paris -
En Direct des Marchés : Société Générale, Imerys, Robertet, Apple, BP Plc, Atos, Gobe Life...
Bolsa de Madrid: Apple y el PPI salvan América
More news

Quotes and Performance

1 day-2.75%
1 week-11.75%
Current month-33.21%
1 month-33.21%
3 months+16.46%
6 months+84.00%
Current year+27.78%
More quotes

Highs and lows

1 week
1.78
Extreme 1.78
2.20
1 month
1.78
Extreme 1.78
2.85
Current year
1.40
Extreme 1.398
3.15
1 year
0.94
Extreme 0.94
3.32
3 years
0.55
Extreme 0.548
5.00
5 years
0.55
Extreme 0.548
5.00
10 years
0.55
Extreme 0.548
5.00
More quotes

Managers and Directors - NFL Biosciences

Managers TitleAgeSince
Bruno Lafont FOU
 Founder - 06-08-31
Ignacio Faus CEO
 Chief Executive Officer - 21-05-18
Guillaume Audema DFI
 Director of Finance/CFO - -
Members of the board TitleAgeSince
Yannick Plétan BRD
 Director/Board Member - 21-05-18
Ignacio Faus CEO
 Chief Executive Officer - 21-05-18
Bruno Lafont FOU
 Founder - 06-08-31
More insiders

Quotes

Date Price Change Volume
24-05-02 1.84 0.00% 42 935
24-04-30 1.84 -2.75% 43,502
24-04-29 1.892 +3.96% 29,139
24-04-26 1.82 -7.61% 118,183
24-04-25 1.97 -4.37% 93,417

Real-time Euronext Paris, April 30, 2024 at 11:09 am EDT

More quotes

Company Profile

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2022, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
Sector
Biotechnology & Medical Research
Calendar
2024-09-29 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.84 EUR
Average target price
4.2 EUR
Spread / Average Target
+128.26%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NFL BIOSCIENCES Stock NFL Biosciences
+27.78% 15.93M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+2.13% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.79% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALNFL Stock